TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66544-0 DO - 10.1016/S0140-6736(05)66544-0 ID - ref1 ER - TY - JOUR AU - Guo, B. AU - Villeneuve, D. J. AU - Hembruff, S. L. AU - Kirwan, A. F. AU - Blais, D. E. AU - Bonin, M. PY - 2004 DA - 2004// TI - Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure JO - Breast Cancer Res Treat. VL - 85 UR - https://doi.org/10.1023/B:BREA.0000021046.29834.12 DO - 10.1023/B:BREA.0000021046.29834.12 ID - Guo2004 ER - TY - JOUR AU - Ringel, I. AU - Horwitz, S. B. PY - 1991 DA - 1991// TI - Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol JO - J Natl Cancer Inst. VL - 83 UR - https://doi.org/10.1093/jnci/83.4.288 DO - 10.1093/jnci/83.4.288 ID - Ringel1991 ER - TY - JOUR AU - Chazard, M. AU - Pellae-Cosset, B. AU - Garet, F. AU - Soares, J. A. AU - Lucidi, B. AU - Lavail, Y. PY - 1994 DA - 1994// TI - Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes JO - Bull Cancer. VL - 81 ID - Chazard1994 ER - TY - JOUR AU - Minotti, G. AU - Menna, P. AU - Salvatorelli, E. AU - Cairo, G. AU - Gianni, L. PY - 2004 DA - 2004// TI - Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity JO - Pharmacol Rev. VL - 56 UR - https://doi.org/10.1124/pr.56.2.6 DO - 10.1124/pr.56.2.6 ID - Minotti2004 ER - TY - JOUR AU - Schinkel, A. H. AU - Roelofs, E. M. AU - Borst, P. PY - 1991 DA - 1991// TI - Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies JO - Cancer Res. VL - 51 ID - Schinkel1991 ER - TY - JOUR AU - Bliek, A. M. AU - Baas, F. AU - Velde-Koerts, T. AU - Biedler, J. L. AU - Meyers, M. B. AU - Ozols, R. F. PY - 1988 DA - 1988// TI - Genes amplified and overexpressed in human multidrug-resistant cell lines JO - Cancer Res. VL - 48 ID - Bliek1988 ER - TY - JOUR AU - Giaccone, G. AU - Gazdar, A. F. AU - Beck, H. AU - Zunino, F. AU - Capranico, G. PY - 1992 DA - 1992// TI - Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression JO - Cancer Res. VL - 52 ID - Giaccone1992 ER - TY - JOUR AU - Jong, S. AU - Zijlstra, J. G. AU - Vries, E. G. AU - Mulder, N. H. PY - 1990 DA - 1990// TI - Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line JO - Cancer Res. VL - 50 ID - Jong1990 ER - TY - JOUR AU - Friesen, C. AU - Fulda, S. AU - Debatin, K. M. PY - 1997 DA - 1997// TI - Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells JO - Leukemia. VL - 11 UR - https://doi.org/10.1038/sj.leu.2400827 DO - 10.1038/sj.leu.2400827 ID - Friesen1997 ER - TY - JOUR AU - Lowe, S. W. AU - Ruley, H. E. AU - Jacks, T. AU - Housman, D. E. PY - 1993 DA - 1993// TI - p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents JO - Cell. VL - 74 UR - https://doi.org/10.1016/0092-8674(93)90719-7 DO - 10.1016/0092-8674(93)90719-7 ID - Lowe1993 ER - TY - JOUR AU - Munro, A. F. AU - Twelves, C. AU - Thomas, J. S. AU - Cameron, D. A. AU - Bartlett, J. M. PY - 2012 DA - 2012// TI - Chromosome instability and benefit from adjuvant anthracyclines in breast cancer JO - Br J Cancer. VL - 107 UR - https://doi.org/10.1038/bjc.2012.232 DO - 10.1038/bjc.2012.232 ID - Munro2012 ER - TY - JOUR AU - Pritchard, K. I. AU - Munro, A. AU - O’Malley, F. P. AU - Tu, D. AU - Li, X. AU - Levine, M. N. PY - 2012 DA - 2012// TI - Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial JO - Breast Cancer Res Treat VL - 131 UR - https://doi.org/10.1007/s10549-011-1840-4 DO - 10.1007/s10549-011-1840-4 ID - Pritchard2012 ER - TY - JOUR AU - Bartlett, J. M. AU - McConkey, C. C. AU - Munro, A. F. AU - Desmedt, C. AU - Dunn, J. A. AU - Larsimont, D. P. PY - 2015 DA - 2015// TI - Predicting anthracycline benefit: TOP2A and CEP17—not only but also JO - J Clin Oncol. VL - 33 UR - https://doi.org/10.1200/JCO.2013.54.7869 DO - 10.1200/JCO.2013.54.7869 ID - Bartlett2015 ER - TY - JOUR AU - Perou, C. M. AU - Sorlie, T. AU - Eisen, M. B. AU - Rijn, M. AU - Jeffrey, S. S. AU - Rees, C. A. PY - 2000 DA - 2000// TI - Molecular portraits of human breast tumours JO - Nature. VL - 406 UR - https://doi.org/10.1038/35021093 DO - 10.1038/35021093 ID - Perou2000 ER - TY - JOUR AU - Sorlie, T. AU - Perou, C. M. AU - Tibshirani, R. AU - Aas, T. AU - Geisler, S. AU - Johnsen, H. PY - 2001 DA - 2001// TI - Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications JO - Proc Natl Acad Sci U S A. VL - 98 UR - https://doi.org/10.1073/pnas.191367098 DO - 10.1073/pnas.191367098 ID - Sorlie2001 ER - TY - JOUR AU - Poole, C. J. AU - Earl, H. M. AU - Hiller, L. AU - Dunn, J. A. AU - Bathers, S. AU - Grieve, R. J. PY - 2006 DA - 2006// TI - Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer JO - N Engl J Med. VL - 355 UR - https://doi.org/10.1056/NEJMoa052084 DO - 10.1056/NEJMoa052084 ID - Poole2006 ER - TY - JOUR AU - Whitfield, M. L. AU - Zheng, L. X. AU - Baldwin, A. AU - Ohta, T. AU - Hurt, M. M. AU - Marzluff, W. F. PY - 2000 DA - 2000// TI - Stem-loop binding protein, the protein that binds the 3′ end of histone mRNA, is cell cycle regulated by both translational and posttranslational mechanisms JO - Mol Cell Biol. VL - 20 UR - https://doi.org/10.1128/MCB.20.12.4188-4198.2000 DO - 10.1128/MCB.20.12.4188-4198.2000 ID - Whitfield2000 ER - TY - JOUR AU - Kanehisa, M. AU - Goto, S. AU - Sato, Y. AU - Kawashima, M. AU - Furumichi, M. AU - Tanabe, M. PY - 2014 DA - 2014// TI - Data, information, knowledge and principle: back to metabolism in KEGG JO - Nucleic Acids Res. VL - 42 UR - https://doi.org/10.1093/nar/gkt1076 DO - 10.1093/nar/gkt1076 ID - Kanehisa2014 ER - TY - JOUR AU - Subik, K. AU - Lee, J. F. AU - Baxter, L. AU - Strzepek, T. AU - Costello, D. AU - Crowley, P. PY - 2010 DA - 2010// TI - The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines JO - Breast Cancer (Auckl) VL - 4 ID - Subik2010 ER - TY - JOUR AU - Győrffy, B. AU - Lanczky, A. AU - Eklund, A. C. AU - Denkert, C. AU - Budczies, J. AU - Li, Q. PY - 2010 DA - 2010// TI - An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients JO - Breast Cancer Res Treat. VL - 123 UR - https://doi.org/10.1007/s10549-009-0674-9 DO - 10.1007/s10549-009-0674-9 ID - Győrffy2010 ER - TY - JOUR AU - Nayak, S. R. AU - Harrington, E. AU - Boone, D. AU - Hartmaier, R. AU - Chen, J. AU - Pathiraja, T. N. PY - 2015 DA - 2015// TI - A role for histone H2B variants in endocrine-resistant breast cancer JO - Horm Cancer. VL - 6 UR - https://doi.org/10.1007/s12672-015-0230-5 DO - 10.1007/s12672-015-0230-5 ID - Nayak2015 ER - TY - JOUR AU - Vardabasso, C. AU - Gaspar-Maia, A. AU - Hasson, D. AU - Pünzeler, S. AU - Valle-Garcia, D. AU - Straub, T. PY - 2015 DA - 2015// TI - Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma JO - Mol Cell VL - 59 UR - https://doi.org/10.1016/j.molcel.2015.05.009 DO - 10.1016/j.molcel.2015.05.009 ID - Vardabasso2015 ER - TY - JOUR AU - Bonenfant, D. AU - Coulot, M. AU - Towbin, H. AU - Schindler, P. AU - Oostrum, J. PY - 2006 DA - 2006// TI - Characterization of histone H2A and H2B variants and their post-translational modifications by mass spectrometry JO - Mol Cell Proteomics. VL - 5 UR - https://doi.org/10.1074/mcp.M500288-MCP200 DO - 10.1074/mcp.M500288-MCP200 ID - Bonenfant2006 ER - TY - JOUR AU - Hembruff, S. L. AU - Laberge, M. L. AU - Villeneuve, D. J. AU - Guo, B. AU - Veitch, Z. AU - Cecchetto, M. PY - 2008 DA - 2008// TI - Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance JO - BMC Cancer. VL - 8 UR - https://doi.org/10.1186/1471-2407-8-318 DO - 10.1186/1471-2407-8-318 ID - Hembruff2008 ER - TY - JOUR AU - Wyrick, J. J. AU - Parra, M. A. PY - 2009 DA - 2009// TI - The role of histone H2A and H2B post-translational modifications in transcription: a genomic perspective JO - Biochim Biophys Acta. VL - 1789 UR - https://doi.org/10.1016/j.bbagrm.2008.07.001 DO - 10.1016/j.bbagrm.2008.07.001 ID - Wyrick2009 ER - TY - JOUR AU - Harris, M. E. AU - Bohni, R. AU - Schneiderman, M. H. AU - Ramamurthy, L. AU - Schumperli, D. AU - Marzluff, W. F. PY - 1991 DA - 1991// TI - Regulation of histone mRNA in the unperturbed cell cycle: evidence suggesting control at two posttranscriptional steps JO - Mol Cell Biol. VL - 11 UR - https://doi.org/10.1128/MCB.11.5.2416 DO - 10.1128/MCB.11.5.2416 ID - Harris1991 ER - TY - JOUR AU - Parra, M. A. AU - Wyrick, J. J. PY - 2007 DA - 2007// TI - Regulation of gene transcription by the histone H2A N-terminal domain JO - Mol Cell Biol. VL - 27 UR - https://doi.org/10.1128/MCB.00742-07 DO - 10.1128/MCB.00742-07 ID - Parra2007 ER - TY - JOUR AU - Parra, M. A. AU - Kerr, D. AU - Fahy, D. AU - Pouchnik, D. J. AU - Wyrick, J. J. PY - 2006 DA - 2006// TI - Deciphering the roles of the histone H2B N-terminal domain in genome-wide transcription JO - Mol Cell Biol. VL - 26 UR - https://doi.org/10.1128/MCB.26.10.3842-3852.2006 DO - 10.1128/MCB.26.10.3842-3852.2006 ID - Parra2006 ER - TY - JOUR AU - Beck, H. C. AU - Nielsen, E. C. AU - Matthiesen, R. AU - Jensen, L. H. AU - Sehested, M. AU - Finn, P. PY - 2006 DA - 2006// TI - Quantitative proteomic analysis of post-translational modifications of human histones JO - Mol Cell Proteomics. VL - 5 UR - https://doi.org/10.1074/mcp.M600007-MCP200 DO - 10.1074/mcp.M600007-MCP200 ID - Beck2006 ER - TY - JOUR AU - Swierniak, A. AU - Kimmel, M. AU - Smieja, J. PY - 2009 DA - 2009// TI - Mathematical modeling as a tool for planning anticancer therapy JO - Eur J Pharmacol. VL - 625 UR - https://doi.org/10.1016/j.ejphar.2009.08.041 DO - 10.1016/j.ejphar.2009.08.041 ID - Swierniak2009 ER - TY - JOUR AU - Norton, L. AU - Simon, R. PY - 1977 DA - 1977// TI - Tumor size, sensitivity to therapy, and design of treatment schedules JO - Cancer Treat Rep. VL - 61 ID - Norton1977 ER - TY - JOUR AU - Norton, L. AU - Simon, R. AU - Brereton, H. D. AU - Bogden, A. E. PY - 1976 DA - 1976// TI - Predicting the course of Gompertzian growth JO - Nature. VL - 264 UR - https://doi.org/10.1038/264542a0 DO - 10.1038/264542a0 ID - Norton1976 ER - TY - JOUR AU - Regel, I. AU - Merkl, L. AU - Friedrich, T. AU - Burgermeister, E. AU - Zimmermann, W. AU - Einwachter, H. PY - 2012 DA - 2012// TI - Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2 JO - Gastroenterology. VL - 143 UR - https://doi.org/10.1053/j.gastro.2012.03.035 DO - 10.1053/j.gastro.2012.03.035 ID - Regel2012 ER - TY - JOUR AU - Groselj, B. AU - Sharma, N. L. AU - Hamdy, F. C. AU - Kerr, M. AU - Kiltie, A. E. PY - 2013 DA - 2013// TI - Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair JO - Br J Cancer. VL - 108 UR - https://doi.org/10.1038/bjc.2013.21 DO - 10.1038/bjc.2013.21 ID - Groselj2013 ER - TY - JOUR AU - Wagner, J. M. AU - Hackanson, B. AU - Lubbert, M. AU - Jung, M. PY - 2010 DA - 2010// TI - Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy JO - Clin Epigenetics. VL - 1 UR - https://doi.org/10.1007/s13148-010-0012-4 DO - 10.1007/s13148-010-0012-4 ID - Wagner2010 ER - TY - JOUR AU - Lee, J. H. AU - Choy, M. L. AU - Marks, P. A. PY - 2012 DA - 2012// TI - Mechanisms of resistance to histone deacetylase inhibitors JO - Adv Cancer Res. VL - 116 UR - https://doi.org/10.1016/B978-0-12-394387-3.00002-1 DO - 10.1016/B978-0-12-394387-3.00002-1 ID - Lee2012 ER - TY - JOUR AU - Gosland, M. P. AU - Gillespie, M. N. AU - Tsuboi, C. P. AU - Tofiq, S. AU - Olson, J. W. AU - Crooks, P. A. PY - 1996 DA - 1996// TI - Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine JO - Cancer Chemother Pharmacol. VL - 37 UR - https://doi.org/10.1007/s002800050434 DO - 10.1007/s002800050434 ID - Gosland1996 ER - TY - JOUR AU - Paridaens, R. AU - Biganzoli, L. AU - Bruning, P. AU - Klijn, J. G. AU - Gamucci, T. AU - Houston, S. PY - 2000 DA - 2000// TI - Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over JO - J Clin Oncol. VL - 18 ID - Paridaens2000 ER - TY - JOUR AU - Simon, R. M. AU - Paik, S. AU - Hayes, D. F. PY - 2009 DA - 2009// TI - Use of archived specimens in evaluation of prognostic and predictive biomarkers JO - J Natl Cancer Inst. VL - 101 UR - https://doi.org/10.1093/jnci/djp335 DO - 10.1093/jnci/djp335 ID - Simon2009 ER -